New Research from EHA23 Points to Similar Effectiveness of Acalabrutinib and Zanubrutinib in R/R CLL Treatment

Although a head-to-head comparison is lacking, a new study presented at EHA23 suggests that acalabrutinib and zanubrutinib are likely comparable in terms of efficacy in treating R/R CLL. Listen to Alan Skarbnik, Director of the Lymphoma and CLL Program at the Novant Health Cancer Institute, North Carolina, sharing the findings of this study.